Zydus Life bags USFDA orphan drug tag for Desidustat indicated for sickle cell disease treatment

February 6, 2026
Uncategorized

Zydus Lifesciences received USFDA Orphan Drug Designation for Desidustat to treat Sickle Cell Disease, with incentives and study data pending publication.

Zydus Life bags USFDA orphan drug tag for Desidustat indicated for sickle cell disease treatment

Leave a ReplyCancel Reply

M&M to set up biggest manufacturing unit in Vidarbha with ₹15,000 crore investment

Dividend stock: P&G Health declares ₹160 dividend including one-time special payout

Gold, silver prices fall: Should investors buy, hold or exit?

Gateway Distriparks Q3: Net profit tanks 85% on consolidation impact; declares dividend

Market ends mostly higher after volatile session; Nifty closes above 25,650